drugset / Trial / NCT02937818
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior platinum-based chemotherapy.
Timeline
- Start
- 2016-11-28
- Primary completion
- 2020-06-22
- Completion
- 2023-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | — | Oral |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Ceralasertib | Small molecule | — | Oral |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Olaparib | Small molecule | — | Oral |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.